Default company panoramic image

Evgen Limited

Development of a novel anti-cancer agent, Sulforadex. Now in Phase I, it is initially being developed for prostate and breast cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Liverpool, England, GB
  • Currency GBP
  • Founded January 2008
  • Employees 4
  • Website

Company Summary

Evgen Limited is developing a novel cancer therapeutic called Sulforadex®, initially for early stage prostate cancer and prevention of recurrence of breast cancer. The product is in Phase I clinical trials. Sulforadex is a patented composition comprising a stabilised form of sulforaphane, a molecule that is well recognised for its therapeutic potential in a broad range of cancers but has hitherto been non-viable as a pharmaceutical.


  • Default avatar
    Barry Clare

    Twenty years experience in the healthcare industry. Former main board director of Boots Company plc. More recently has established several private equity transactions that have successfully exited.

  • Default avatar
    Stephen Franklin
    Chief Executive

    Over 15 years commercial experience in the life sciences industries. Founder and former CEO of Provexis plc. Previously part of ANGLE plc and held a business development role with Manchester University Biotech incubator.

  • Default avatar
    David Howat
    Chief Development officer

    Over 18 years relevant experience in pharmaceutical industry R&D. Head of project management for KS Biomedix Holdings, a biopharmaceutical company developing a pipeline of drugs for a range of cancer indications. Director of preclinical development for NicOx SA.

  • Default avatar
    Alan Barge
    Chief Medical Advisor

    Currently Chief Medical Officer of Singapore based ASLAN Pharmaceuticals PTE. Was VP and head of Oncology & Infection at AstraZeneca. Prior to AZ, Alan was global Medical Director for Amgen Inc.

  • Default avatar
    Sue Foden

    Founder member of Cancer Research UK and former CEO of Cancer Research Campaign Technology Limited and Cancer Research Ventures Limited. Maintains a portfolio of NED & Advisory board positions.

  • Default avatar
    Barry Furr
    Chief Scientific Advisor

    Former Chief Scientist of AstraZeneca. A reproductive biologist and endocrinologist. Barry worked on Tamoxifen. Both Zoladex & Casodex for prostate cancer were discovered in his laboratory. Barry was awarded an OBE in 2000 for his contribution to cancer research and holds a number of prestigious positions.


  • Default avatar
    Turner Parkinson LLP, Manchester
    Default avatar
    Grunberg and Co, London

Previous Investors

  • Default avatar
    EV Group (Rising Stars Growth Fund II)
    Default avatar
    SPARK Impact (North West Fund for Biomedical)
    Default avatar
    Sarum Oncology Fund, Imprimatur Capital and high net worth syndicate